이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ono Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 6/6

Ono Pharmaceutical 의 총 주주 지분은 ¥798.6B 이고 총 부채는 ¥0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 ¥913.7B 및 ¥115.1B 입니다. Ono Pharmaceutical 의 EBIT는 ¥159.9B 이며 이자보상배율은 -42.1 입니다. ¥204.6B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

JP¥0

부채

이자 보상 비율	-46.5x
현금	JP¥204.60b
주식	JP¥798.61b
총 부채	JP¥115.06b
총 자산	JP¥913.67b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Jun 24

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Mar 04

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Feb 27

재무 상태 분석

단기부채: 4528 의 단기 자산 ( ¥413.6B )이 단기 부채( ¥103.6B ).

장기 부채: 4528 의 단기 자산( ¥413.6B )이 장기 부채( ¥11.4B ).

부채 대 자본 내역 및 분석

부채 수준: 4528 부채가 없습니다.

부채 감소: 4528 5년 전에 부채가 없었습니다.

부채 범위: 4528 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 4528 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Ono Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Price target increased by 7.4% to JP¥2,935

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 20% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥33.00 per share at 2.4% yield

Price target decreased by 7.4% to JP¥3,292

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥33.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Consensus EPS estimates fall by 11%

Now 21% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 11,000,000 shares, representing 2.2% for ¥30,000 million.

Second quarter 2022 earnings released: EPS JP¥44.51 (vs JP¥36.77 in 2Q 2021)

Upcoming dividend of JP¥28.00 per share

Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

First quarter 2022 earnings released: EPS JP¥48.23 (vs JP¥43.07 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Upcoming dividend of JP¥22.50 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

New 90-day low: JP¥3,020

Third quarter 2021 earnings released: EPS JP¥53.37 (vs JP¥38.09 in 3Q 2020)

Revenue and earnings beat expectations

ONO Receives a Manufacturing and Marketing Approval of Adlumiz (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

Ono Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021

Ono Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Oct 29, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기